Medical Care Technologies, Inc. (OTC Pink:MDCE) Announces Completion of AI-Based Consumer App, Now in iOS App Store Review

MESA, ARIZONA / ACCESS Newswire / December 17, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is pleased to announce that its first AI-based consumer app in the food and nutrition space has completed testing and is now under review in the iOS App Store. The app will launch in 127 countries and 30 languages, with a Google Play Store review planned before January 1st.

Early Beta Invite and Partnerships
Investors will be invited to an exclusive early beta release once the app’s title and theme are announced. We’re partnering with iHeartRadio and top app marketing agencies for a successful debut.

CEO Quote
“This is just the beginning. AI has fundamentally transformed our company, and we’re not the same organization we were even a year ago,” said Marshall Perkins III, CEO of MDCE.

Safe Harbor Statement
This press release includes forward-looking statements subject to risks and uncertainties. More details can be found on our website.

About Us
Medical Care Technologies, Inc. develops AI-driven health and wellness applications. Visit www.medicalcaretechnologies.com.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies, Inc. (OTC Pink: MDCE)

View the original press release on ACCESS Newswire

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

5 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

8 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

8 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

8 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

8 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

8 hours ago